(Q33372250)

English

Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease). (English)

1 reference

Europe PubMed Central

26 July 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

Pieter E Postmus

8

object named as

P E Postmus

1 reference

Europe PubMed Central

26 July 2017

author name string

E C J Phernambucq

1

1 reference

Europe PubMed Central

26 July 2017

B Biesma

2

1 reference

Europe PubMed Central

26 July 2017

E F Smit

3

1 reference

Europe PubMed Central

26 July 2017

M A Paul

4

1 reference

Europe PubMed Central

26 July 2017

A vd Tol

5

1 reference

Europe PubMed Central

26 July 2017

F M Schramel

6

1 reference

Europe PubMed Central

26 July 2017

R J Bolhuis

7

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

8 August 2006

1 reference

Europe PubMed Central

26 July 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

British Journal of Cancer

1 reference

Europe PubMed Central

26 July 2017

95

1 reference

Europe PubMed Central

26 July 2017

4

1 reference

Europe PubMed Central

26 July 2017

470-474

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603289

0 references

Repopulation of cancer cells during therapy: an important cause of treatment failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360660

21 June 2018

Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360660

21 June 2018

The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360660

21 June 2018

Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360660

21 June 2018

Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360660

21 June 2018

Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360660

21 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360660

21 June 2018

Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360660

21 June 2018

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360660

21 June 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360660

21 June 2018

An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603289

21 January 2018

Endoscopic ultrasound added to mediastinoscopy for preoperative staging of patients with lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603289

21 January 2018

Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603289

21 January 2018

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603289

21 January 2018

Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603289

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603289

21 January 2018

Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical re-staging predictive of pathological staging?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603289

21 January 2018

Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603289

21 January 2018

Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603289

21 January 2018

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603289

21 January 2018

Primary tumors and mediastinal lymph nodes after neoadjuvant concurrent chemoradiotherapy of lung cancer: serial CT findings with pathologic correlation

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erythropoietin for anaemia in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6603289

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33372250&oldid=1985078379"